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Background and purpose   Recent meta-analyses have suggested 
similar wound infection rates when using single- or multiple-dose 
antibiotic  prophylaxis  in  the  operative  management  of  closed 
long bone fractures. In order to assist clinicians in choosing the 
optimal prophylaxis strategy, we performed a cost-effectiveness 
analysis comparing single- and multiple-dose prophylaxis. 
Methods   A cost-effectiveness analysis comparing the two pro-
phylactic strategies was performed using time horizons of 60 days 
and 1 year. Infection probabilities, costs, and quality-adjusted life 
days (QALD) for each strategy were estimated from the literature. 
All costs were reported in 2007 US dollars. A base case analysis 
was performed for the surgical treatment of a closed ankle frac-
ture. Sensitivity analysis was performed for all variables, includ-
ing probabilistic sensitivity analysis using Monte Carlo simula-
tion.
Results   Single-dose prophylaxis results in lower cost and a 
similar amount of quality-adjusted life days gained. The single-
dose strategy had an average cost of $2,576 for an average gain of 
272 QALD. Multiple doses had an average cost of $2,596 for 272 
QALD gained. These results are sensitive to the incidence of sur-
gical site infection and deep wound infection for the single-dose 
treatment arm. Probabilistic sensitivity analysis using all model 
variables also demonstrated preference for the single-dose strat-
egy.
Interpretation   Assuming similar infection rates between the 
prophylactic groups, our results suggest that single-dose prophy-
laxis is slightly more cost-effective than multiple-dose regimens 
for the treatment of closed fractures. Extensive sensitivity analy-
sis demonstrates these results to be stable using published meta-
analysis infection rates. 

The use of prophylactic antibiotics in the surgical treatment 
of closed long bone fractures is well-established (Boyd et al. 
1973, Burnett et al. 1980, Gatell et al. 1984); however, the 
duration and dosage of prophylaxis varies substantially among 
surgeons (Gatell et al. 1987, Buckley et al. 1990, Garotta et 
al. 1991). Previous meta-analyses comparing single- and mul-
tiple-dose prophylaxis for surgical fixation of fractures have 
failed to demonstrate the superiority of either prophylactic 
strategy (Southwell-Keely et al. 2004, Gillespie et al. 2006, 
Slobogean et al. 2008). Although a definitive prophylactic rec-
ommendation cannot be made from these studies, the pooled 
results demonstrate that surgical site infections in this popula-
tion are uncommon and that any potential differences in infec-
tion rates between the strategies is likely to be small. Based 
on the low incidence of infection observed in the pooled stud-
ies, it has been suggested that over 25,000 patients would be 
needed to demonstrate superiority of either strategy, making a 
clinical trial unlikely (Slobogean et al. 2008). 
Decision  analysis  techniques  can  offer  an  alternative 
method for answering clinical questions when performance 
of a clinical trial is not feasible (Brauer and Waters 2007). 
Cost-effectiveness  analysis  uses  economic  and  preference-
weighted health state data to mathematically model clinical 
decisions (Russell et al. 1996). From this analysis, a preferred 
treatment strategy can be suggested using commonly accepted 
criteria (Siegel et al. 1996, Weinstein et al. 1996). Addition-
ally, this type of economic evaluation allows one to identify 
the numeric boundaries of key variables where its conclusions 
become unstable. A review of the basic principles and impor-
tance of economic evaluations was recently published in this 
journal (Dijksman et al. 2008).
In  order  to  explore  potentially  small  differences  in  effi-
cacy between prophylactic dosing practices and to estimate 
the economic and quality of life implications of perioperative 
prophylactic  decisions,  we  performed  a  cost-effectiveness 
analysis comparing single-dose and multiple-dose antibiotic 
prophylaxis for the surgical treatment of closed fractures.Acta Orthopaedica 2010; 81 (1): 256–262  257
Materials and methods
Overview
We developed a decision-analysis model to compare the cost-
effectiveness of single-dose antibiotic prophylaxis to that of a 
multiple-dose perioperative regimen during the surgical treat-
ment of closed fractures. The analysis was performed from 
a healthcare payer perspective using 60-day and 1-year time 
horizons. Probabilities, costs, and health-related quality of life 
outcome data were obtained from the authors’ institution and 
estimated from the literature (Table 1).
Model design
A decision tree reflecting the choice of antibiotic prophylaxis 
and possible perioperative outcomes was created using Treeage 
Pro 2007 (Treeage Software Inc., Williamstown, MA) (Figure 
1). We felt that surgical site infection and Clostridium difficile-
associated diarrhea (CDAD) were potential perioperative com-
plications that could vary based on the initial choice of prophy-
laxis (Anand et al. 1994). The decision tree reflects the interac-
tion of the following outcomes: (1) wound infection and CDAD; 
(2) wound infection and no CDAD; (3) no wound infection but 
with CDAD; and (4) no wound infection and no CDAD. 
Antibiotic prophylaxis is based on intravenous administra-
tion of 1 g cefazolin, with the multiple-dose regime consisting 
of 4 perioperative doses. Superficial surgical site infections are 
treated with 10 days of oral antibiotics (40 doses, cephalexin 
500 mg four times daily), and deep wound infections receive 
surgical debridement and antibiotic coverage for 6 weeks (126 
doses, cefazolin 1 g three times daily). The model assumes that 
wound infections and CDAD are treated without recurrence. 
It also assumes that the prophylaxis regimen chosen does not 
alter the fracture union rate in either treatment arm. 
Perioperative probabilities
Surgical site infection. The probability of developing a wound 
infection was estimated from a recently reported meta-analy-
sis of single-dose versus multiple-dose antibiotic prophylaxis 
for  surgical  fixation  of  closed  fractures  (Slobogean  et  al. 
2008). The incidence of surgical site infection was estimated 
to be 2.5% for single-dose prophylaxis and 2.0% for multiple 
doses, with no statistically significant difference between the 
2 prophylactic regimes (risk ratio: 1.24; 95% CI: 0.60–2.60). 
Pooled estimates for the distribution of superficial and deep 
wound infections were also used (Table 1).
Table 1. Model variables
Variable   Base  case   Range   References
Incidence of SSI   
  Single-dose prophylaxis   0.025   0.01–0.06   Garotta et al. 1991, Gatell et al. 1987, Slobogean et al. 2008
  Superficial   0.66   a   Slobogean et al. 2008
  Deep   0.34   0.3–0.6   Slobogean et al. 2008
  Multiple-dose prophylaxis   0.02   0.01–0.06   Garotta et al. 1991, Slobogean et al. 2008, Ali and Raza 2006
  Superficial   0.57   a   Slobogean et al. 2008
  Deep   0.43   0.3–0.6   Slobogean et al. 2008
Incidence of Abx-related C. difficile   
  Risk per dose of 1st generation cephalosporin   0.00028  0.0001–0.0013   Anand et al. 1994
  Doses to treat superficial SSI    40   28–56 
    Risk of C. difficile   0.011   0.008–0.016 
  Doses to treat deep SSI   126   84–168 
    Risk of C. difficile   0.035   0.023–0.047
Costs (2007 USD)   
  ORIF ankle fracture   2,481   2,000–10,000   Bhandari et al. 2004
  Preparation and dose of cefazolin          9   5–15  Garrelts et al. 1994 b
  Single-dose prophylaxis         9  5–15 
  Multiple-dose prophylaxis        36   20–60 
  Superficial SSI   2,319   500–5,000  Zoutman et al. 1998
  Deep SSI   5,255   3,000–15,000   Zoutman et al. 1998
  C. difficile   4,689   2,270–14,717  Kyne et al. 2002, O’Brien et al. 2007
Quality Adjusted Life Days (QALD)   
  Ankle fracture    272   204–285   Bhandari et al. 2004
  C. difficile   268   124–284   Kyne et al. 2002, Pepin et al. 2005
  Superficial SSI   272   204–285 
  Superficial SSI and C. difficile   268   124–284   Kyne et al. 2002, Pepin et al. 2005
  Deep SSI   267   123–283   Kuntz et al. 2000
  Deep SSI and C. difficile   263   122–282   Kyne et al. 2002, Pepin et al. 2005, Kuntz et al. 2000
a 1 – probability of deep infection.
b cost obtained from institution’s pharmacy.
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C. difficile associated diarrhea. The probability of devel-
oping CDAD reflects an estimated antibiotic dose-dependent 
risk. Anand et al. (1994) reported the incidence of C. diffi-
cile infection following the administration of cephalosporins. 
First-generation cephalosporins had the lowest incidence of 
CDAD  (0.03%  per  dose  administered).  The  probability  of 
developing CDAD for each branch of the decision tree is equal 
to the product of the number of antibiotic doses received and 
the risk per dose administered (Table 1).
Reference case
In  accordance  with  consensus  recommendations,  we  con-
ducted the cost-effectiveness analysis using a reference case 
(Siegel et al. 1996, Weinstein et al. 1996). The reference case 
analysis was based on a healthy 52-year-old male undergo-
ing operative fixation of an unstable Weber B lateral malleolus 
fracture of the ankle.
Outcomes
Health Related Quality of Life (HRQoL). We evaluated the 
effectiveness of each prophylactic intervention using utility 
data obtained from the literature. Utilities reflect preference-
weighted measures of quality of life and are commonly gener-
ated by standard gamble or time-tradeoff techniques; generic 
utility measurement tools are also frequently used (Torrance 
1987, Bell et al. 2001). Quality adjusted life-years (QALYs) 
can then be calculated from these data by summing the prod-
ucts of the utility for a given health state and the duration 
of time spent in each health state (Torrance 1987, Bell et al. 
2001). Since 60-day and 1-year time horizons were used, and 
the time spent in each health state was measured in days, qual-
ity-adjusted life days (QALDs) are reported instead of QALYs. 
Within the 60-day and 1-year time horizon models, the maxi-
mum possible QALDs were 60 and 365, respectively. 
The QALDs gained for each respective branch of the tree 
were estimated from relevant published literature (Table 2). 
Bhandari  et  al.  (2004)  reported  utilities  of  0.34  and  0.78, 
respectively,  for  the  immediate  and  one-year  postoperative 
periods in a cohort of operatively treated ankle fractures. The 
postoperative ankle fracture health state was estimated as a 
weighted average of these two utilities, with an individual 
spending 30 days in the 0.34 health state and the remainder of 
the time horizon in the higher 0.78 utility health state. 
Pepin et al. (2005) recently reported that C. difficile-associ-
ated diarrhea resulted in a mean hospital stay of 7.0 days in a 
cohort of 1,125 patients aged 18–64 years with no important 
Figure 1. Decision tree representing the single- or multiple-dose prophylaxis decision for the surgical treatment of a closed fracture. The probability 
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co-morbidities. The HRQL associated with CDAD was esti-
mating based on the utility associated with being hospitalized 
(Kuntz et al. 2000).
To estimate the effect of a surgical site infection, we felt that 
a superficial infection would not reduce the QALDs gained. 
However, deep wound infection has been associated with a 
mean increase in length of stay of 10 days (Zoutman et al. 
1998), and the associated utility for hospitalization was again 
used to quantify this health state (Kuntz et al. 2000). 
For health states that involved multiple perioperative com-
plications, the total QALDs gained was estimated by sum-
ming  the  utilities  for  each  health  state  sequentially  rather 
concurrently. For example, an individual who develops a deep 
wound infection and CDAD spends 10 days in the deep wound 
infection health state, then 7 days in the CDAD state, before 
completing the remainder of the model’s time horizon in the 
weighted postoperative ankle fracture state (Table 2).
Costs
All costs are reported in 2007 US dollars and were inflated as 
necessary using the Consumer Price Index inflation calculator 
(available  online,  http://www.bls.gov/cpi/). The  mean  costs 
for treatment of an ankle fracture, C. difficile-associated diar-
rhea, and superficial or deep wound infection were obtained 
from published reports (Anand et al. 1994, Zoutman et al. 
1998, Kyne et al. 2002, O’Brien et al. 2007). The cost per 
dose of antibiotic prophylaxis included the costs of materials 
and preparation as reported by Garrelts et al. (1994), and the 
current pharmaceutical cost of cefazolin in our hospital (Table 
1).
Sensitivity analysis
Sensitivity analysis allows researchers to explore the impact 
of uncertainty on their results, and is an important component 
of economic analyses (Walker and Fox-Rushby 2001). One-
way sensitivity analysis alters the value of a single variable 
over a clinically plausible range to determine its effect on the 
model’s outcome. If the result of the analysis changes signifi-
cantly when the variable is altered, then the model is “sensi-
tive” to its value. Conversely, if sensitivity analysis does not 
alter the results of the cost-effectiveness analysis, then one 
may be confident that the results from the analysis will be 
stable over most clinically plausible ranges. Probabilistic sen-
sitivity analysis using Monte Carlo simulation techniques is 
another method for assessing the robustness of results (Doubi-
let et al. 1985). In this type of analysis, the model calculations 
are repeated several thousand times, with differing values for 
each variable selected from a plausible distribution. 
One-way sensitivity analysis was performed for each event 
probability and outcome variable based on the clinically plau-
sible  ranges  described  in  Table  1.  Probabilistic  sensitivity 
analysis was performed using a Monte Carlo simulation of 
100,000 trials. Event probabilities and outcomes were sampled 
from a triangular distribution using the base case and range 
values described in Table 1. A threshold willingness to pay 
(WTP) of $137 per incremental QALD ($50,000 per QALY) 
gained was used to choose a preferred strategy. 
Results
The quality adjusted life days (QALDs) associated with each 
possible health state were equivalent, and the results of the 
analysis suggested that differences between the two prophy-
lactic regimens were based on cost (Table 3). These results 
were observed in both the 60-day and the 1-year time hori-
zons. Open reduction and internal fixation of a closed ankle 
fracture using a single-dose prophylaxis strategy was found 
to be associated with a cost of $2,576 and 272 QALDs in a 1-
year time horizon (and 34 QALDs in a 60-day time horizon). 
Using multiple-dose antibiotic prophylaxis resulted in a cost 
of $2,596 and, similarly, 272 QALDs in a 1-year time horizon 
(and 34 QALDs in a 60-day time horizon).
One-way sensitivity analysis of each variable throughout 
its clinically plausible range showed the results to be stable 
Table 2. Health-related quality of life adjustments
Event   Health state (utilities)   QALD
Ankle fracture   0.34 for 30 days
  0.78 for remainder of time horizon   272
C. difficile   0.30 for 7 days
  0.34 for 30 days
  0.78 for remainder of time horizon   268
Superficial SSI   0.34 for 30 days
  0.78 for remainder of time horizon   272
Superficial SSI 
   and C. difficile   0.30 for 7 days
  0.34 for 30 days
  0.78 for remainder of time horizon   268
Deep SSI   0.30 for 10 days
  0.34 for 30 days
  0.78 for remainder of time horizon   267
Deep SSI and C. difficile   0.25 for 7 days
  0.30 for 10 days
  0.34 for 30 days
  0.78 for remainder of time horizon   263
QALD: quality-adjusted life-days; 
SSI: surgical site infection.
Table 3. Base case analysis
Prophylaxis   Cost ($)   QALD   ICER
Single   2,576.49   272  –
Multiple  2,595.84   272   Dominated
QALD: quality-adjusted life-days; 
ICER: incremental cost-effectiveness ratio.260  Acta Orthopaedica 2010; 81 (2): 256–262
for most model variables. However, the preferred strategy was 
sensitive to two variables related to receiving single-dose pro-
phylaxis: (1) the probability of surgical site infection (pSSI), 
and (2) the probability of a deep wound infection. Multiple-
dose prophylaxis is preferred when the pSSI for the single-
dose arm exceeds 3%; it is also preferred when the single-dose 
deep wound infection proportion is greater than 55%. These 
results are based on a multiple-dose pSSI of 2% and a deep 
wound infection proportion of 43% (Table 1).
Two-way sensitivity analysis was also performed by simul-
taneously varying the pSSI for the single- and multiple-dose 
strategies. Based on the willingness to pay of $137 per incre-
mental QALD ($50,000 per QALY), one can determine the 
preferred  strategy  with  different  combinations  of  pSSI  for 
single- and multiple-dose prophylaxis (Figure 2A). Figure 2B 
allows similar analysis while simultaneously varying the pro-
portion of deep wound infection for each prophylactic strat-
egy.
Probabilistic  sensitivity  analysis  also  suggested  that  the 
single-dose strategy is preferred most often. Figure 3 shows 
the incremental cost-effectiveness ratio (ICER) for the mul-
tiple-dose strategy compared to single-dose prophylaxis for 
each Monte Carlo simulation. Approximately 70% of the sim-
ulations resulted in an ICER above the $137 per QALD thresh-
old, and most of these results were located in the “dominated” 
upper-left quadrant (where multiple-dose is more expensive 
and less effective). Consequently, increasing the willingness 
to pay threshold did not alter the result.
Further analysis was also performed to determine which 
variables most influenced the model’s overall costs and effec-
tiveness. As expected, the cost of treating an ankle fracture and 
the utility associated with the ankle fracture health state were 
found to have the greatest influence on the extent of either 
intervention’s cost-effectiveness. 
Discussion
Our cost-effectiveness analysis was performed to help deter-
mine the optimum prophylaxis strategy during the treatment 
of closed long bone fractures. Our results suggest that single-
dose prophylaxis is more cost-effective than a multiple-dose 
strategy; however, the small difference between the two strate-
gies is primarily based on a narrow difference in cost. These 
results are sensitive to the incidence of wound infection in the 
Figure  3.  Results  of  Monte  Carlo  probabilistic  sensitivity  analysis. 
The incremental cost-effectiveness ratio for multiple-dose prophylaxis 
compared to the single-dose strategy is shown. A “willingness to pay” 
threshold of $137 per incremental QALD (dashed line) and the 95% 
confidence interval (ellipse) are also shown. 
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Figure 2. Results of two-way sensitivity analysis. The incidence of surgical site infection (A) and the 
proportion of deep wound infection (B) for each prophylaxis strategy is varied throughout the range 
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single-dose group and its resulting proportion of deep wound 
infections.  However,  if  the  incidence  of  wound  infections 
between the two strategies is similar, as suggested by several 
meta-analyses, then the results of this model remain robust.
We have not found any previous reports comparing the cost-
effectiveness of two commonly used prophylactic antibiotic 
regimens in perioperative orthopedic care. The results of this 
study  are  consistent  with  previous  clinical  trial  and  meta-
analysis data suggesting that the efficacies of the prophylactic 
strategies are similar, and complement these reports by com-
paring the strategies based on their cost-effectiveness. Our 
results also outline the clinical variables that determine when 
one prophylactic strategy would be preferred.
Despite the fact that we considered the additional costs asso-
ciated with treating surgical wound infections or C. difficile-
associated diarrhea, the difference in cost between the strate-
gies was approximately $20. In addition, the quality-adjusted 
life-days  for  each  prophylactic  decision  were  estimated  to 
be equal in both time horizon models. The similar costs and 
QALDs gained for each strategy occurred for several reasons: 
(1) wound infection is a relatively infrequent complication; 
(2) important adverse events related to prophylactic antibi-
otics (such as C. difficile-associated diarrhea) are extremely 
uncommon; (3) the time spent in health states associated with 
an adverse event (lower utility) is typically short-lived. Thus, 
even  when  using  a  substantially  shorter  time  horizon,  the 
QALDs for each prophylactic strategy remain equal.
When  clinical  events  are  uncommon,  decision  analysis 
offers the benefit of extensive sensitivity analysis. One par-
ticular strength of our report is that the results were scruti-
nized by performing one-way sensitivity analysis on all model 
variables, and further two-way analysis on selected variables. 
In addition, the more sophisticated Monte Carlo method of 
simulation allowed all variables to be varied over 100,000 rep-
etitions. Finally, using two different time horizon models, we 
were able to determine that the differences between the strate-
gies were not influenced by the time horizon considered. As 
a result of using multiple methods of sensitivity analysis, the 
stability of the results and its limitations were demonstrated. 
A further strength of our study was the ability to use wound 
infection rates from meta-analysis data (rather than a single 
trial) since the incidence of wound infection was a sensitive 
variable.
Despite the relative strength of our analysis, its results should 
be interpreted in the context of the model design. We based the 
utilities associated with each health state on relevant estimates 
used in previous studies; we found no published literature that 
directly  quantified  the  utility  associated  with  postoperative 
wound infection or antibiotic-associated C. difficile diarrhea. 
This lack of available data highlights the need for additional 
research to define the effect of postoperative complications on 
patient outcomes and healthcare costs in orthopedic trauma.
In summary, assuming similar infection rates between the 
prophylactic groups, this analysis suggests that single-dose 
prophylaxis is slightly more cost-effective than multiple-dose 
regimens for the treatment of closed fractures. This result is 
based mainly on cost, and extensive sensitivity analysis has 
demonstrated these results to be stable using published meta-
analysis infection rates. Further work to collect utility data in 
the postoperative period, particularly from patients experienc-
ing complications, would be of benefit to clinicians and health 
economists.
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